Trials / Unknown
UnknownNCT04387695
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Single-center Randomized Controlled Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
Detailed description
HCC Patients classified as BCLC stage C present with PVTT, and the recommended first-line treatment is systemic therapy with sorafenib according to updated Barcelona Clinical Liver cancer (BCLC) treatment algorithms.However, recent data from observational studies suggest that the combination of TACE and SBRT would be as effective as sorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT+TACE+Sorafenib | SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later |
| DRUG | Sorafenib | Sorafenib 800 mg/day orally |
Timeline
- Start date
- 2020-04-30
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2020-05-14
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04387695. Inclusion in this directory is not an endorsement.